{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:48:35Z","timestamp":1792928915084,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Applied Pharmacometrics Training \u2013 Africa Program, c\/o Pharmacometrics Africa NPC, Cape Town, South Africa"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10928-024-09959-y","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:35:03Z","timestamp":1737765303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer\u2019s disease using ADNI"],"prefix":"10.1007","volume":"52","author":[{"given":"Marwa E.","family":"Elhefnawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Patson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Mouksassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goonaseelan","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shcherbinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Chigutsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelina","family":"Gueorguieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"9959_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2021.06.014","volume":"106","author":"J Pfeil","year":"2021","unstructured":"Pfeil J et al (2021) Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer\u2019s disease. Neurobiol Aging 106:119\u2013129","journal-title":"Neurobiol Aging"},{"issue":"9","key":"9959_CR2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 367(9):795\u2013804","journal-title":"N Engl J Med"},{"issue":"2","key":"9959_CR3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR et al (2013) Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurol 12(2):207\u2013216","journal-title":"The Lancet Neurol"},{"issue":"3","key":"9959_CR4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K (2014) The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron 84(3):608\u2013622","journal-title":"Neuron"},{"issue":"4","key":"9959_CR5","doi-asserted-by":"crossref","first-page":"fcab226","DOI":"10.1093\/braincomms\/fcab226","volume":"3","author":"CM Fiford","year":"2021","unstructured":"Fiford CM et al (2021) Presumed small vessel disease, imaging and cognition markers in the Alzheimer\u2019s Disease Neuroimaging Initiative. Brain Commun 3(4):fcab226","journal-title":"Brain Commun"},{"issue":"3","key":"9959_CR6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jalz.2010.03.006","volume":"6","author":"PS Aisen","year":"2010","unstructured":"Aisen PS et al (2010) Clinical Core of the Alzheimer\u2019s Disease Neuroimaging Initiative: progress and plans. Alzheimer\u2019s Dement 6(3):239\u2013246","journal-title":"Alzheimer\u2019s Dement"},{"issue":"5","key":"9959_CR7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jalz.2018.12.009","volume":"15","author":"EC Edmonds","year":"2019","unstructured":"Edmonds EC et al (2019) Early versus late MCI: improved MCI staging using a neuropsychological approach. Alzheimer\u2019s Dement 15(5):699\u2013708","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"9959_CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13195-022-01067-8","volume":"14","author":"CJ Park","year":"2022","unstructured":"Park CJ et al (2022) Predicting conversion of brain \u03b2-amyloid positivity in amyloid-negative individuals. Alzheimer\u2019s Res Ther 14(1):129","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"1","key":"9959_CR9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3233\/ADR-210005","volume":"5","author":"C Fowler","year":"2021","unstructured":"Fowler C et al (2021) Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u2019s disease. J Alzheimer\u2019s Dis Rep 5(1):443\u2013468","journal-title":"J Alzheimer\u2019s Dis Rep"},{"issue":"1","key":"9959_CR10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL et al (2011) Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease. Ann Neurol 69(1):181\u2013192","journal-title":"Ann Neurol"},{"issue":"4","key":"9959_CR11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL et al (2013) Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. The Lancet Neurol 12(4):357\u2013367","journal-title":"The Lancet Neurol"},{"issue":"5","key":"9959_CR12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2012.07.004","volume":"9","author":"YY Lim","year":"2013","unstructured":"Lim YY et al (2013) A\u03b2 amyloid, cognition, and APOE genotype in healthy older adults. Alzheimer\u2019s Dement 9(5):538\u2013545","journal-title":"Alzheimer\u2019s Dement"},{"key":"9959_CR13","unstructured":"Kumar, A., et al., Alzheimer disease (nursing). 2021."},{"key":"9959_CR14","unstructured":"Iaccarino, L. et al., A practical oveview of the use of amyloid-PET Centiloid values in clinical trials and research, Alz&Dem, 2024, submitted."},{"issue":"9","key":"9959_CR15","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","volume":"96","author":"WJ Jagust","year":"2021","unstructured":"Jagust WJ et al (2021) Initiative, Temporal dynamics of \u03b2-amyloid accumulation in aging and Alzheimer disease. Neurology 96(9):e1347\u2013e1357","journal-title":"Neurology"},{"key":"9959_CR16","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1093\/brain\/awac213","volume":"145","author":"TJ Betthauser","year":"2022","unstructured":"Betthauser TJ et al (2022) Alzheimer\u2019s Disease Neuroimaging Initiative, Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain 145:4065\u20134079","journal-title":"Brain"},{"issue":"6","key":"9959_CR17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/acn3.782","volume":"6","author":"L Iaccarino","year":"2019","unstructured":"Iaccarino L et al (2019) Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET. Annals Clin Trans Neurol 6(6):1113\u20131120","journal-title":"Annals Clin Trans Neurol"},{"issue":"5","key":"9959_CR18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/brain\/awv029","volume":"138","author":"SJ Vos","year":"2015","unstructured":"Vos SJ et al (2015) Prevalence and prognosis of Alzheimer\u2019s disease at the mild cognitive impairment stage. Brain 138(5):1327\u20131338","journal-title":"Brain"},{"key":"9959_CR19","unstructured":"Epstein, A.J., Estimating Progression Rates Across the Spectrum of Alzheimer\u2019s Disease for Amyloid-Positive Individuals Using National Alzheimer\u2019s Coordinating Center Data. 2021."},{"issue":"5054","key":"9959_CR20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256(5054):184\u2013185","journal-title":"Science"},{"issue":"5580","key":"9959_CR21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297(5580):353\u2013356","journal-title":"Science"},{"issue":"6","key":"9959_CR22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"issue":"1","key":"9959_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321","journal-title":"N Engl J Med"},{"key":"9959_CR24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40495-016-0066-x","volume":"2","author":"SF Cook","year":"2016","unstructured":"Cook SF, Bies RR (2016) Disease progression modeling: key concepts and recent developments. Current Pharmacol Rep 2:221\u2013230","journal-title":"Current Pharmacol Rep"},{"issue":"6","key":"9959_CR25","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/alz.12876","volume":"19","author":"I Gueorguieva","year":"2023","unstructured":"Gueorguieva I et al (2023) Disease progression model using the integrated Alzheimer\u2019s disease rating scale. Alzheimer\u2019s Dement 19(6):2253\u20132264","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1\u20132","key":"9959_CR26","first-page":"22","volume":"14","author":"H Posner","year":"2017","unstructured":"Posner H et al (2017) Outcomes assessment in clinical trials of Alzheimer\u2019s disease and its precursors: readying for short-term and long-term clinical trial needs. Innov Clin Neurosci 14(1\u20132):22","journal-title":"Innov Clin Neurosci"},{"issue":"228","key":"9959_CR27","doi-asserted-by":"crossref","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling RA et al (2014) The A4 study: stopping AD before symptoms begin? Sci Trans Med 6(228):228fs13-228fs13","journal-title":"Sci Trans Med"},{"key":"9959_CR28","unstructured":"Hooker, A., M. Karlsson, and E. Jonsson, Xpose4: tools for nonlinear mixed-effect model building and diagnostics. R package version 4.6. 1. 2014."},{"key":"9959_CR29","doi-asserted-by":"crossref","unstructured":"Mould, D.R., Developing models of disease progression. Pharmacometrics: the science of quantitative pharmacology. Wiley, Hoboken, 2007: p. 547\u2013581.","DOI":"10.1002\/9780470087978.ch21"},{"key":"9959_CR30","unstructured":"Katsube, T., et al. Characterization of Stepwise Covariate Model Building Combined with Cross-Validation. in PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. 2012."},{"issue":"6","key":"9959_CR31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"A-G Dosne","year":"2016","unstructured":"Dosne A-G et al (2016) Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn 43(6):583\u2013596","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"9959_CR32","first-page":"1","volume":"2","author":"N Holford","year":"2013","unstructured":"Holford N (2013) A time to event tutorial for pharmacometricians. CPT: Pharmacomet Syst Pharmacol 2(5):1\u20138","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"issue":"12","key":"9959_CR33","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I et al (2018) Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer\u2019s Dement 14(12):1565\u20131571. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1353","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"9959_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1041610207006412","volume":"20","author":"B Reisberg","year":"2008","unstructured":"Reisberg B, Gauthier S (2008) Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer\u2019s disease. Int Psychogeriatr 20(1):1\u201316","journal-title":"Int Psychogeriatr"},{"issue":"4","key":"9959_CR35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/archgenpsychiatry.2010.30","volume":"67","author":"F Jessen","year":"2010","unstructured":"Jessen F et al (2010) Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiat 67(4):414\u2013422","journal-title":"Arch Gen Psychiat"},{"issue":"1","key":"9959_CR36","first-page":"S98","volume":"4","author":"B Reisberg","year":"2008","unstructured":"Reisberg B et al (2008) The pre\u2013mild cognitive impairment, subjective cognitive impairment stage of Alzheimer\u2019s disease. Alzheimers Dement 4(1):S98\u2013S108","journal-title":"Alzheimers Dement"},{"issue":"1","key":"9959_CR37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jalz.2012.09.017","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F et al (2014) AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement 10(1):76\u201383","journal-title":"Alzheimers Dement"},{"key":"9959_CR38","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2147\/NDT.S174517","volume":"14","author":"YM Choe","year":"2018","unstructured":"Choe YM et al (2018) Subjective memory complaint as a useful tool for the early detection of Alzheimer\u2019s disease. Neuropsychiat Dis Treat 14:2451\u20132460","journal-title":"Neuropsychiat Dis Treat"},{"key":"9959_CR39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fnagi.2013.00011","volume":"5","author":"SL Risacher","year":"2013","unstructured":"Risacher SL et al (2013) The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci 5:11","journal-title":"Front Aging Neurosci"},{"key":"9959_CR40","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.630502","volume":"15","author":"MA Husain","year":"2021","unstructured":"Husain MA, Laurent B, Plourde M (2021) APOE and Alzheimer\u2019s disease: from lipid transport to physiopathology and therapeutics. Front Neurosci 15:630502","journal-title":"Front Neurosci"},{"issue":"16","key":"9959_CR41","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 278(16):1349\u20131356","journal-title":"JAMA"},{"issue":"10","key":"9959_CR42","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","volume":"74","author":"SC Neu","year":"2017","unstructured":"Neu SC et al (2017) Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol 74(10):1178\u20131189","journal-title":"JAMA Neurol"},{"issue":"3","key":"9959_CR43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002254","volume":"14","author":"J Qian","year":"2017","unstructured":"Qian J et al (2017) APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med 14(3):e1002254","journal-title":"PLoS Med"},{"issue":"1","key":"9959_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0546-4","volume":"12","author":"MS Baek","year":"2020","unstructured":"Baek MS et al (2020) Effect of APOE \u03b54 genotype on amyloid-\u03b2 and tau accumulation in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 12(1):1\u201312","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"2","key":"9959_CR45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.apsb.2021.10.002","volume":"12","author":"BR Troutwine","year":"2022","unstructured":"Troutwine BR et al (2022) Apolipoprotein E and Alzheimer\u2019s disease. Acta Pharmaceutica Sinica B 12(2):496\u2013510","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"9","key":"9959_CR46","doi-asserted-by":"crossref","first-page":"864","DOI":"10.30773\/pi.2021.0104","volume":"18","author":"SH Joo","year":"2021","unstructured":"Joo SH, Lee CU (2021) Cerebral amyloid positivity prediction models using clinical data in subjects with mild cognitive impairment and dementia. Psychiat Investig 18(9):864","journal-title":"Psychiat Investig"},{"issue":"3","key":"9959_CR47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ana.24454","volume":"78","author":"BW Patterson","year":"2015","unstructured":"Patterson BW et al (2015) Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 78(3):439\u2013453","journal-title":"Ann Neurol"},{"issue":"6012","key":"9959_CR48","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega KG et al (2010) Decreased clearance of CNS \u03b2-amyloid in Alzheimer\u2019s disease. Science 330(6012):1774\u20131774","journal-title":"Science"},{"issue":"4","key":"9959_CR49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","volume":"12","author":"AS Association","year":"2016","unstructured":"Association AS (2016) 2016 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dementia 12(4):459\u2013509","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"1","key":"9959_CR50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1196\/annals.1297.005","volume":"1019","author":"EH Corder","year":"2004","unstructured":"Corder EH et al (2004) The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci 1019(1):24\u201328","journal-title":"Ann N Y Acad Sci"},{"key":"9959_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fdata.2020.00024","author":"LL Raket","year":"2020","unstructured":"Raket LL (2020) Statistical disease progression modelling in Alzheimer Disease. Front Big Data. https:\/\/doi.org\/10.3389\/fdata.2020.00024","journal-title":"Front Big Data"},{"key":"9959_CR52","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/psp4.12974","volume":"12","author":"S Jamalian","year":"2023","unstructured":"Jamalian S, Dolton M, Chanu P, Ramakrishnan V, Franco Y, Wildsmith K, Manser P, Ten E, Jin JY, Quartino A, Hsu JC (2023) Modeling Alzheimer\u2019s disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB. CPT Pharmacometrics Syst Phamacol 12:1029\u20131042","journal-title":"CPT Pharmacometrics Syst Phamacol"},{"key":"9959_CR53","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimer\u2019s and Dementia 20:5143\u20135169","journal-title":"Alzheimer\u2019s and Dementia"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09959-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-024-09959-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09959-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:05:46Z","timestamp":1739639146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-024-09959-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9959"],"URL":"https:\/\/doi.org\/10.1007\/s10928-024-09959-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5306168\/v1","asserted-by":"object"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sergey Shcherbinin, Emmanuel Chigutsa, Ivelina Gueorguieva are all full-time employees and minor shareholders of Eli Lilly and Company. Marwa E.Elhefnawy, Noel Patson, Samer Mouksassi and Goonaseelan (Colin) Pillai have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"ADNI data used in this study was approved by the Institutional Review Boards of all of the participating institutions. Informed written consent was obtained from all participants at each site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"15"}}